CLASS ACTION UPDATE for EQT, CAH and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Friday, 16. August 2019 21:43

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

EQT Corporation (NYSE: EQT)
Class Period:
June 19, 2017 - October 24, 2018
Lead Plaintiff Deadline: August 26, 2019
Join the action: https://www.zlk.com/pslra-1/eqt-corporation-loss-form?wire=3

Allegations: EQT Corporation made materially false and/or misleading statements throughout the class period and/or failed to disclose :  (1) land acquired by the Rice Energy merger was not contiguous with the Company’s previously held acreage, which reduced the purported synergy benefits; (2) the purported longer lateral wells were not feasible because of intervening third-party parcels or prior drilling by EQT, Rice, or third parties; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the EQT Corporation class action contact jlevi@levikorsinsky.com.

Cardinal Health, Inc. (NYSE: CAH)
Class Period:
March 2, 2015 - May 2, 2018
Lead Plaintiff Deadline: September 30, 2019
Join the action: https://www.zlk.com/pslra-1/cardinal-health-inc-loss-form?wire=3

Allegations: During the class period, Cardinal Health, Inc. made materially false and/or misleading statements and/or failed to disclose : 1) following Cardinal's acquisition of Cordis, the RFID [radio-frequency identification] inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis’s performance were never implemented across Cordis; 2) Cordis’s antiquated and ineffective global supply chain was causing operational and inventory problems at Cordis; 3) as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; 4) the Company materially overstated Cordis’s inventory balances; 5) Cordis was not “performing well” and its integration was not “on track,” “going incredibly well” or “largely on plan"; and 6) to correct Cordis’s deficiencies, the Company would have to make substantial investments in Cordis’s IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.

To learn more about the Cardinal Health, Inc. class action contact jlevi@levikorsinsky.com.

CVS Health Corporation (NYSE: CVS)
Class Period:
on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for their Aetna shares in connection with CVS’s acquisition of Aetna on November 28, 2018.
Lead Plaintiff Deadline: October 15, 2019
Join the action: https://www.zlk.com/pslra-1/cvs-health-corporation-loss-form-2?wire=3

According to the filed complaint, CVS made false and/or misleading statements in connection with its acquisition of Aetna and/or failed to disclose : (a) by the end of 2017, CVS's financial condition and expected earnings had deteriorated as a result of rising costs and poor results being experienced in the long-term care ("LTC") unit associated with the 2015 acquisition of Omnicare; (b) in 2017, deteriorating conditions and prospects in CVS 's LTC unit prompted CVS to undertake hasty acquisitions of LTC pharmacies to compensate for the declining LTC business and/or mask the expected LTC goodwill impairment ahead of the planned Acquisition; (c) although negative LTC performance factors prompted CVS and the CVS Individual Defendants to make hasty LTC pharmacy acquisitions in 2017, those same negative factors were being overlooked and ignored for purposes of undertaking, disclosing, and reporting the results of LTC goodwill impairment tests throughout 2017, in violation of GAAP; (d) the LTC goodwill being carried on CVS's books as a result of the Omnicare acquisition was being carried at inflated values that would require billions of dollars in impairment charges that would be charged against earnings; and (e) as a result of the foregoing, CVS's true business metrics and financial prospects were not as the Offering Documents represented.

To learn more about the CVS Health Corporation class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Primary Logo

Related Links: 
Author:
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.